[go: up one dir, main page]

MX2018008469A - Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. - Google Patents

Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Info

Publication number
MX2018008469A
MX2018008469A MX2018008469A MX2018008469A MX2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A
Authority
MX
Mexico
Prior art keywords
devices
end portion
methods
medicament container
disorderswith
Prior art date
Application number
MX2018008469A
Other languages
English (en)
Inventor
Patel Samirkumar
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of MX2018008469A publication Critical patent/MX2018008469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos y dispositivos para tratar la AMD húmeda, CNV, AMD húmeda asociada con CNV y/o AMD húmeda asociada con RVO en un sujeto humano que lo necesite. En ciertos aspectos, los dispositivos que sé proporcionan en la presente incluyen un recipiente de medicamento que define un lumen configurado para contener un medicamento, una porción del extremo distante del recipiente de medicamento que incluye una porción de acoplamiento configurada para acoplarse de manera desmontable a un conjunto de aguja, una porción del extremo próximo del recipiente de medicamento que incluye una pestaña y un hombro longitudinal; un conjunto de pistón que incluye una porción del extremo distante dispuesta de manera móvil dentro del lumen del recipiente de medicamento; y un asa acoplada a una porción del extremo próximo del conjunto de pistón.
MX2018008469A 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. MX2018008469A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276543P 2016-01-08 2016-01-08
US201662324708P 2016-04-19 2016-04-19
PCT/US2017/012757 WO2017120601A1 (en) 2016-01-08 2017-01-09 Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics

Publications (1)

Publication Number Publication Date
MX2018008469A true MX2018008469A (es) 2018-11-09

Family

ID=59274052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008469A MX2018008469A (es) 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Country Status (9)

Country Link
EP (1) EP3400014A1 (es)
JP (1) JP2019501200A (es)
KR (1) KR20180101488A (es)
CN (1) CN108778330A (es)
AU (1) AU2017206114A1 (es)
BR (1) BR112018013805A2 (es)
CA (1) CA3010862A1 (es)
MX (1) MX2018008469A (es)
WO (1) WO2017120601A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
CN106214321B (zh) 2010-10-15 2018-08-28 科尼尔赛德生物医学公司 用于进入眼睛的装置
EA034963B1 (ru) 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
IL262207B1 (en) 2016-04-15 2025-09-01 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019067540A1 (en) * 2017-09-27 2019-04-04 Regenxbio Inc. TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB
AU2018388439B2 (en) * 2017-12-20 2021-05-20 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
BR112020022610A2 (pt) * 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
CN110693886B (zh) * 2018-07-09 2022-12-06 天津医科大学 防治脑海绵状血管畸形病变的药物
FI3897595T3 (en) * 2018-12-20 2023-03-31 Thea Lab NUTRITIONAL OPHTHALMIC COMPOSITION FOR THE TREATMENT OF RETINA DISEASES WITH A NEOVASCULAR COMPONENT
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR20200101160A (ko) * 2019-02-19 2020-08-27 전남대학교산학협력단 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법
CN113966236A (zh) * 2019-04-03 2022-01-21 再生生物股份有限公司 眼睛病状的基因疗法
CN110522909B (zh) * 2019-09-30 2024-02-20 安徽省立医院 一种协同增强抗her2阳性肿瘤效果的药物组合
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020383580A1 (en) * 2019-11-11 2022-05-12 Cstone Pharmaceuticals Pharmaceutical combination and use thereof
IL293469B2 (en) * 2019-12-19 2024-04-01 Active Biotech Ab Compounds for treatment of eye diseases associated with excessive vascularisation
CN119745879A (zh) * 2020-02-19 2025-04-04 科尼尔赛德生物医学公司 包含阿西替尼的组合物和治疗眼部疾病的方法
WO2021257193A1 (en) * 2020-06-15 2021-12-23 Opko Pharmaceuticals, Llc Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion
WO2022245739A1 (en) * 2021-05-17 2022-11-24 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN113546176B (zh) * 2021-06-30 2024-03-15 南通大学 一种特异性用于抑制眼内血管新生药物合成方法
CN116087525B (zh) * 2022-11-16 2025-10-28 东南大学 一种即时检测Tau蛋白的微腔结构高灵敏SERS芯片的制备方法
CN118356501A (zh) * 2023-01-19 2024-07-19 百奥泰生物制药股份有限公司 一种复方制剂及其应用
WO2024167694A2 (en) * 2023-02-06 2024-08-15 Celularity Inc. Placental extracellular matrices for ocular delivery of ophthalmic therapeutic agents
TW202515597A (zh) * 2023-06-23 2025-04-16 美商再生元醫藥公司 用於血管新生眼睛病症之治療之延長高劑量vegf拮抗劑方案

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194471A1 (en) * 2011-05-27 2013-12-30 Novartis Ag Method of treating vision disorders
EP2817031A4 (en) * 2012-02-22 2015-08-05 Tufts College COMPOSITIONS AND METHOD FOR THE ORGANIC ADMINISTRATION OF A THERAPEUTIC ACTIVE SUBSTANCE
EA034963B1 (ru) * 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
WO2015095772A2 (en) * 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
KR102511477B1 (ko) * 2014-06-17 2023-03-16 클리어사이드 바이오메디컬, 인코포레이드 안구 후부 질환을 치료하기 위한 방법 및 디바이스

Also Published As

Publication number Publication date
KR20180101488A (ko) 2018-09-12
EP3400014A1 (en) 2018-11-14
WO2017120601A1 (en) 2017-07-13
BR112018013805A2 (pt) 2018-12-11
JP2019501200A (ja) 2019-01-17
AU2017206114A1 (en) 2018-08-02
CN108778330A (zh) 2018-11-09
CA3010862A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
MX2018008469A (es) Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.
MX2016016836A (es) Metodos y dispositivos para tratar trastornos oculares posteriores.
PH12014502792A1 (en) Soft tip cannula
MX2017000920A (es) Dispositivos magneticos para anastomosis y metodos de entrega.
IN2015DN02530A (es)
MX2016016070A (es) Introductor y guia de cateter con aguja tangencial subretinal.
WO2015164839A3 (en) System and method for safety syringe
USD738490S1 (en) Prosthesis insertion bellow
MX2020008980A (es) Dispositivo de administracion de farmacos.
EP4324414A3 (en) Devices and methods for treating the skin using a rollerball or a wicking member
WO2014127389A3 (en) Thrombectomy catheter
MX383017B (es) Jeringa de clip
NZ630742A (en) A patient interface
MX2016017028A (es) Canula de diametro variable y metodos para el control de la profundidad de insercion para administracion de medicamentos.
GB201318950D0 (en) Deployment Catheter
BR112015017366A2 (pt) dispositivo médico e método para facilitar a seleção de um implante de anuloplastia
MY182497A (en) Ocular implant delivery device and method
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
MX2017001673A (es) Prenda de compresion medica terapeutica y metodo.
MX2020011003A (es) Valvula para dilatador y ensamble de cubierta.
CO6500125A1 (es) Suministro de curcumina por derivacion
MY192494A (en) Vaginal composition and use thereof
MX384815B (es) Dispositivo para insertar una canula de punta roma bajo la piel de un paciente.
WO2016123496A3 (en) Suspension implant
WO2017079325A3 (en) Injection devices and systems and methods for using them